Biotech News

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Therapeutics (NRSN)NeuroSense Therapeutics2026-06-25 13:46 ESTCompany update

NRSN (NRSN) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is nrsn.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Announces Pricing of Insider-Led PIPE Financing

JAGXJaguar Health2026-06-25 13:46 EST

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

View all latest news

NeuroSense Therapeutics

NeuroSense Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

NRSNNeuroSense Therapeutics2026-06-26 01:15 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

NRSNNeuroSense Therapeutics2026-06-26 01:15 EST

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

NRSNNeuroSense Therapeutics2026-06-26 01:15 EST

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NRSNNeuroSense Therapeutics2026-06-26 01:15 EST

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NRSNNeuroSense Therapeutics2026-06-26 01:15 EST

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States